ERBB2 and breast cancer: Trastuzumab emtansine (T-DM1) is a humanized monoclonal antibody-drug conjugate that has been approved for the treatment of metastatic breast cancers that are positive for human epidermal growth factor receptor 2 (HER2) [66].